Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

Data from the Phase II non-responder study were presented on April 15, 2007 at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) held in Barcelona, Spain and on May 21, 2007 at Digestive Disease Week (DDW) 2007 held in Washington, DC.

On June 26, 2007, Schering-Plough advised us that they would not be entering into a second period of exclusivity to negotiate the terms of a license agreement for celgosivir at that time. MIGENIX is now in various stages of discussions with other interested parties for the partnering of celgosivir.

A Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection who have not received prior treatment for their infection is ongoing. The focus of this study is on viral kinetics, pharmacokinetics, safety and tolerability of celgosivir in combination with peginterferon alfa-2b with ribavirin. As reported previously, enrollment in the study has been slower than anticipated. Interim 4-week data from the study are expected in approximately 10 patients in October 2007, with guidance for 12-week data to be provided in conjunction with the 4-week data.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. An Investigational New Drug (IND) application is planned to be submitted to the US FDA in the first quarter of 2008 for the future development of celgosivir.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, is conducting a Phase II rosacea clinical trial in the United States. The Phase II trial is a randomized, vehicle-controlled, double-blind, multi-center study designed to evaluate the safety and
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/25/2014)... 2014 At the request of the ... 60-day extension for the public comment period (Docket No. ... Model Aircraft established by Congress as part of the ... extension establishes the new deadline for comments as September ... Transportation/FAA notice published in the Federal Register on July ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Calabasas, CA (PRWEB) July 24, 2014 ... advancing the Global Supply Chain of the biotech ... annual SCM Innovation Awards, brought to you by ... premiere global organization of supply chain management professionals ... be given to stakeholders of the Biotech industry ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... , , DUBLIN, Ohio, ... to acquire the assets of privately held Biotech, an operator ... the Southwestern United States. , , Cardinal ... pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. These ...
... ... for Jatropha Promotion & Biodiesel (CJP) a big breakthrough in the search for a viable ... of successful field trials, CJP is now happy to announce the much awaited commercial release ... ...
... ... Terrosa Technologies, a provider of Cloud and SaaS migration services ... sales, marketing and distribution responsibilities with Integrated Clinical Solutions for ... Trial Management System (CTMS) tool for the pharmaceutical clinical research ...
Cached Biology Technology:Cardinal Health Completes Biotech Acquisition 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3
(Date:7/24/2014)... arose have been maintained in our cells today according to ... today in the Journal of Biological Chemistry reveals ... animals still perform ancient reactions thought to have been responsible ... ago. , The primordial soup theory suggests that life began ... combination of metals, gases from the atmosphere and some form ...
(Date:7/24/2014)... work with a new drug that successfully treated lupus in ... received a $250,000 grant to expand his research to a ... a wider range of autoimmune diseases., Chandra Mohan, Hugh Roy ... UH, previously published a study in Arthritis Research & Therapy ... lupus in mice and reduced the number of cases of ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... turtles have been slow to give up the secrets ... For decades, paleontologists who study fossils and molecular biologists ... more closely related to birds and crocodiles or to ... Biological Laboratory in Bar Harbor, Maine, and their colleagues ...
... Bethesda, Md. (July 25, 2011)It,s no secret that ... a bevy of recent research suggests that these positive ... a new review article highlighting the results of more ... this topic, Michelle W. Voss, of the University of ...
... One of the latest attempts to boost the ... in which patients receive a therapeutic injection of their ... clinical trials for melanoma and neuroblastoma, has its limitations: ... outside the body for future re-injection is extremely expensive ...
Cached Biology News:Discovery places turtles next to lizards on family tree 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 3Universal donor immune cells 2
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
E2F2 protein...
Biology Products: